9,10-dimethyl-1,2-benzanthracene has been researched along with mofarotene in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eliason, JF; Hartmann, D; Horii, I; Inoue, T; Kubota, A; Teelmann, K | 1 |
| Eliason, JF; Klaus, M; Teelmann, K; Tsukaguchi, T | 1 |
2 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and mofarotene
| Article | Year |
|---|---|
The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of cyclophosphamide.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Cyclophosphamide; Drug Interactions; Female; Hematopoiesis; Hematopoietic Stem Cells; Mammary Neoplasms, Experimental; Morpholines; Rats; Rats, Sprague-Dawley; Retinoids | 1993 |
Comparison of the therapeutic effects of a new arotinoid, Ro 40-8757, and all-trans- and 13-cis-retinoic acids on rat breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Disease Models, Animal; Eating; Female; Mammary Neoplasms, Experimental; Morpholines; Rats; Rats, Sprague-Dawley; Retinoids; Tretinoin | 1993 |